NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading LNTH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity within the healthcare sector. The current thesis state is intact, supported by strong recent financial performance and a focus on revenue growth.
The market appears to have priced in a neutral valuation, with expectations slightly below peers. The valuation is characterized as cheap compared to competitors, suggesting that there may be room for improvement in market perceptions.
Management has shown a commitment to improving operating income and enhancing cash flow, with recent results indicating progress in these areas. However, the earnings miss in the last quarter suggests challenges in achieving the desired revenue growth trajectory.
The long-term thesis hinges on the performance of sector bellwethers like HLN, TEVA, and ZTS. If these companies continue to perform well, it could provide a favorable backdrop for LNTH. Conversely, any negative guidance from these peers could impact LNTH's momentum.
Overall, LNTH's fundamentals and sector dynamics present a stable outlook for the next 1 to 3 years. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that recent financial performance remains strong. There are no current threats to the thesis.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: A change in adjusted EPS guidance can show how much management believes in future earnings.
Confirms one read:Management raises adjusted EPS guidance to above $5.25 for 2026. This shows strong performance.
Confirms the other:Management cuts adjusted EPS guidance to below $5.00. This shows there are operational issues.
Why it matters: Hitting revenue goals is important for investor trust and stock performance.
Confirms:Q2 revenue meets or exceeds the guidance range of $1.4 billion to $1.45 billion.
Disproves:Q2 revenue falls below the guidance range.
Why it matters: Sustained revenue growth is crucial for Lantheus's long-term strategy. It shows the effectiveness of their product portfolio.
Confirms:Q2 2026 revenue growth exceeds 1.5% compared to Q2 2025.
Disproves:Q2 2026 revenue growth is below 1.5% compared to Q2 2025.
Why it matters: Approval of LNTH-2501 is crucial for expanding the product portfolio and revenue streams.
Confirms:FDA grants approval for LNTH-2501, leading to product launch and revenue generation.
Disproves:FDA denies approval or delays it past June 29. This affects growth expectations.
Why it matters: A drop in sector growth could impact Lantheus's performance and outlook.
Confirms:Sector revenue growth reported below 8% year over year.
Disproves:Sector revenue growth remains above 8% year over year.
Why it matters: Higher cash from operations would show Lantheus is managing its capital well.
Confirms:Cash from operations increases by at least 10% quarter over quarter.
Disproves:Cash from operations declines or stays flat.
Why it matters: More cash from operations helps Lantheus invest in growth and pay off debt.
Confirms:Cash from operations exceeds $130M in Q2.
Disproves:Cash from operations drops below $120M in Q2.
Why it matters: DEFINITY sales are growing. This shows the market likes it and can increase revenue.
Confirms:Q2 sales of DEFINITY increase year over year by more than 6.8%.
Disproves:Q2 sales of DEFINITY decline or grow less than 6.8% year over year.
Why it matters: The launch of PYLARIFY TruVu is key to revenue growth. It could boost market share in PET imaging.
Confirms:PYLARIFY TruVu launched well. Customers are using it, and sales are over $50 million.
Disproves:Launch is delayed or sales are below $20 million. This shows weak market acceptance.
Why it matters: Higher operating income helps Lantheus make more money.
Confirms:Operating income goes above 75% of the target.
Disproves:Operating income stays below 70% of the target.
Why it matters: If PNT2003 gets approved, Lantheus will have more products. This could help future earnings.
Confirms:FDA grants full approval for PNT2003, allowing for its market launch.
Disproves:FDA denies approval or delays the decision beyond Q3 2026.
Why it matters: Higher operating income means better cost control and efficiency. This helps profits.
Confirms:Operating income increases from Q1 2026 to Q2 2026.
Disproves:Operating income declines or remains flat from Q1 2026 to Q2 2026.
